1. At a Glance
Granules India Ltd (NSE: GRANULES, BSE: 532482) just reported a blockbuster Q2FY26 with a 34% YoY revenue jump to ₹12,970 Mn, EBITDA of ₹2,782 Mn, and a PAT of ₹1,306 Mn. The stock currently trades around ₹551, giving it a market cap of ₹13,369 Cr, and a P/E of 26.2x, which is just about half of some large-cap peers like Divi’s or Torrent Pharma.
For a company that once made bulk paracetamol by the ton, Granules is now mixing innovation with ambition — and a bit of IT drama (more on that later). With return on equity (ROE) at 13.9%, ROCE at 15.1%, and OPM steady at 20.8%, the numbers are tidy, the capex is chunky (₹600 Cr planned in FY25), and the leadership is changing faster than a pill dissolving in water.
Its Q2FY26 result is a serious upgrade from the ransomware-hit quarters of FY24 — like an antivirus update for the balance sheet. The 34% profit surge isn’t just from better operations, but also from new product launches, geographic expansion, and a healthy dose of recovery post cyber chaos.
So, what’s cooking at this Hyderabad-based pharma dynamo? Let’s pop the data capsule and find out.
2. Introduction – When Paracetamol Meets Profitability
There’s something poetic about Granules India. It began as a humble bulk drug maker (read: generic paracetamol vendor), and now it’s running a 7-factory global operation supplying 60+ molecules to 300+ customers across 80+ countries. The numbers look so good, even the auditors must be smiling while checking depreciation schedules.
But this isn’t just another Indian pharma story. Over the last decade, Granules has evolved from a commodity API grinder to a value-added formulation giant — from PFI packets to finished dosages, from tonnage to precision. FY24 marked a turning point, as Finished Dosages rose to 64% of revenue, overtaking APIs and PFIs. That’s like going from “raw material supplier” to “Amazon Prime of pill delivery.”
Of course, not everything was smooth. The company’s IT ransomware attack in May 2023 was like a pharma-version of demonetization — everything froze. Systems went down, production halted, and ERP files probably screamed “Ctrl+Alt+Del.” But post that crisis, Granules came back like a phoenix covered in FDA paperwork, rebuilding digital infrastructure and scaling up its U.S. presence.
Now, as of FY26, the company stands on solid ground with a diversified portfolio, ambitious capex, and global leadership in several CNS and OTC products. If pharma had a “Comeback of the Year” award, Granules would be a top nominee.
3. Business Model – WTF Do They Even Do?
Granules’ business is divided into three major lines — all legal, all FDA-inspected, and all profitable (mostly):
- Finished Dosages (64% in FY24)
- Think tablets, caplets, bilayered pills, and capsules — the stuff that ends up in your medicine cabinet.
- The company produces rapid-release, extended-release, and press-fit capsules.
- This segment’s share jumped from 52% in FY22, thanks to value-added products and exports to regulated markets.
- Active Pharmaceutical Ingredients (API) (22% in FY24)
- The raw chemistry of drugs. Granules is a global supplier of paracetamol, metformin, guaifenesin, and methocarbamol — all essential medicines you’ve definitely swallowed at some point.
- But this segment has seen a gradual decline in share, signaling a strategic move toward formulations where margins don’t make auditors cry.
- Pharmaceutical Formulation Intermediates (PFI) (14% in FY24)
- The middle child — the semi-finished ingredient that can directly go into production lines. Granules is one of India’s largest PFI manufacturers with 6 tons of batch capacity.
With 7 manufacturing units (6 in India, 1 in the U.S.), Granules
